Oral lovastatin attenuates airway inflammation and mucus secretion in ovalbumin-induced murine model of asthma.

Allergy Asthma Immunol Res

School of Traditional Chinese Medicine, Chang Gung University, Kwei-Shan, Tao-Yuan, Taiwan. ; Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital at Lin-Kuo, Tao-Yuan, Taiwan.

Published: November 2014

AI Article Synopsis

  • Lovastatin is a cholesterol-lowering drug that also reduces airway hyperresponsiveness and inflammation in an asthma model using mice.
  • The study showed that lovastatin decreases the expression of genes related to inflammation, mucus production, and eosinophil infiltration in the lungs.
  • Lovastatin’s effectiveness requires a high dosage to lower specific IgE levels and suppress Th2 cytokines, indicating its potential benefits in managing asthma symptoms.

Article Abstract

Purpose: Lovastatin is an effective inhibitor of cholesterol synthesis. A previous study demonstrated that lovastatin can also suppress airway hyperresponsiveness (AHR) in murine model of asthma. We aimed to investigate the effect of lovastatin on mucus secretion and inflammation-associated gene expression in the lungs of murine model of asthma.

Methods: Female BALB/c mice were sensitized and challenged with ovalbumin (OVA) by intraperitoneal injection, and orally administered lovastatin from days 14 to 27 post-injection. Gene expression in lung tissues was analyzed using real-time polymerase chain reaction. AHR and goblet cell hyperplasia were also examined. BEAS-2B human bronchial epithelial cells were used to evaluate the effect of lovastatin on the expression of cell adhesion molecules, chemokines, and proinflammatory cytokines in vitro.

Results: We showed that lovastatin inhibits the expression of Th2-associated genes, including eotaxins and adhesion molecules, in the lungs of murine model of asthma. Mucin 5AC expression, eosinophil infiltration and goblet cell hyperplasia were significantly decreased in the lung tissue of murine model of asthma treated with lovastatin. Furthermore, lovastatin inhibited AHR and expression of Th2-associated cytokines in bronchoalveolar lavage fluid. However, a high dose (40 mg/kg) of lovastatin was required to decrease specific IgE to OVA levels in serum, and suppress the expression of Th2-associated cytokines in splenocytes. Activated BEAS-2B cells treated with lovastatin exhibited reduced IL-6, eotaxins (CCL11 and CCL24), and intercellular adhesion molecule-1 protein expression. Consistent with this, lovastatin also suppressed the ability of HL-60 cells to adhere to inflammatory BEAS-2B cells.

Conclusions: These data suggest that lovastatin suppresses mucus secretion and airway inflammation by inhibiting the production of eotaxins and Th2 cytokines in murine model of asthma.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214976PMC
http://dx.doi.org/10.4168/aair.2014.6.6.548DOI Listing

Publication Analysis

Top Keywords

murine model
24
model asthma
20
mucus secretion
12
lovastatin
12
expression th2-associated
12
airway inflammation
8
expression
8
gene expression
8
lungs murine
8
goblet cell
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!